Smith & Nephew plc (SNN) is a Medical - Devices company in the Healthcare sector, currently trading at $34.35. It has a SharesGrow Score of 69/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of SNN = $60.44 (+76% from the current price, the stock appears undervalued). Analyst consensus target is SNN = $38 (+9.2% upside).
Valuation: SNN trades at a trailing Price-to-Earnings (P/E) of 22.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.98.
Financials: revenue is $6.2B, +5.8%/yr average growth. Net income is $626M, growing at +42.2%/yr. Net profit margin is 10.1% (healthy). Gross margin is 68% (-2.5 pp trend).
Balance sheet: total debt is $3.3B against $5.3B equity (Debt-to-Equity (D/E) ratio 0.63, moderate). Current ratio is 2.57 (strong liquidity). Debt-to-assets is 31.8%. Total assets: $10.5B.
Analyst outlook: 6 / 22 analysts rate SNN as buy (27%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 69/100 (Pass), Growth 83/100 (Pass), Past 100/100 (Pass), Health 67/100 (Partial), Moat 71/100 (Pass), Future 40/100 (Partial), Income 55/100 (Partial).
